Internal MedicineChất Ức Chế PDE4BFIBRONEER-IPF
Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial
By MedXY|Mar 31, 2026
An in-depth analysis of the FIBRONEER-IPF trial’s extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosi
